Feb 28 (Reuters) - Britain's health regulator said on

Friday it has approved Moderna's ( MRNA ) vaccine for

respiratory syncytial virus in adults 60 years and older.

The shot, branded as mRESVIA, is for the prevention of lower

respiratory tract disease in older adults, the Medicines and

Healthcare products Regulatory Agency (MHRA) said.

RSV is a common virus that spreads very easily and causes

infections that can be mild, with cold-like symptoms, but can

also cause more serious problems, such as lung infections and

pneumonia.

Older adults are at risk of more serious complications that

could lead to hospital admission and even death.

GSK's vaccine Arexvy and Pfizer's ( PFE ) shot

Abrysvo are approved for use in individuals over the age of 60

in the UK.